Suppr超能文献

低剂量氨鲁米特联合氢化可的松的内分泌效应——一种最佳激素抑制方案

Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen.

作者信息

Harris A L, Dowsett M, Cantwell B M, Sainsbury J R, Needham G, Farndon J, Wilson R

出版信息

Breast Cancer Res Treat. 1986;7 Suppl:S69-72.

PMID:2943338
Abstract

The endocrine effects of aminoglutethimide 125 mg twice daily and hydrocortisone 20 mg twice daily were assessed in 45 postmenopausal women with advanced breast cancer. Oestrone and oestradiol levels were suppressed by 60% within 2 weeks and suppression was maintained for more than 6 months of chronic treatment. In contrast to conventional dose AG with hydrocortisone, or low dose AG without hydrocortisone, delta 4 androstenedione was suppressed by 65%. This effect may contribute to optimal oestrogen suppression.

摘要

对45名绝经后晚期乳腺癌女性患者评估了每日两次服用125毫克氨鲁米特及每日两次服用20毫克氢化可的松的内分泌效应。雌酮和雌二醇水平在2周内被抑制了60%,且在超过6个月的长期治疗中抑制作用得以维持。与常规剂量氨鲁米特联合氢化可的松或不使用氢化可的松的低剂量氨鲁米特相比,δ4雄烯二酮被抑制了65%。这一效应可能有助于实现最佳的雌激素抑制效果。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验